Anavex Life Sciences Corp (AVXL)

[dia76ca]

Let us assume that Lecanemab and 2-73 are equally efficacious.
And let us assume that patients and care givers are equally happy to spend several hours every two weeks getting a Lecanemab infusion as spending several seconds every day taking a 2-73 pill.
And let us assume that the very serious safety concerns about Lecanemab don't matter.
We are left with a very important difference in COST.
Lecanemab is a monoclonal antibody and therefore very expensive to produce.
And it must be delivered every two weeks via infusion. Infusion takes time and infusion centers are usually very overburdened with Covid and cancer patients...and an added COST.
2-73 is very inexpensive to produce and taking a daily pill adds no cost.
Might it be fair to suggest that 2-73 treatment could cost about 1/10 the cost of Lecanemab treatment?
Who cares? Both patients and health care systems!